Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 291 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Tamoxifen citrate Clear all
Completed Phase 4 Interventional Results available

Tamoxifen for the Treatment of Unfavorable Bleeding in Contraceptive Implant Users

NCT02070692
View directory record Official record
Conditions
Menstruation Disturbances
Interventions
Tamoxifen, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 2, 2026, 2:30 AM EDT
Completed Phase 2 Interventional Results available

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer

NCT03078751
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib, Adjuvant endocrine therapy, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
33
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Oct 2, 2026, 2:30 AM EDT
Active, not recruiting Phase 2 Interventional

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

NCT04569747
View directory record Official record
Conditions
HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer
Interventions
Pertuzumab+TRASTUZUMAB, ADJUVANT ENDOCRINE THERAPY
Combination Product · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
32
States / cities
Stamford, Connecticut • Miami, Florida • Atlanta, Georgia + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 2, 2026, 2:30 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of Everolimus Beyond Progression

NCT02269670
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
everolimus, anastrozole, letrozole, tamoxifen citrate, fulvestrant, megestrol acetate
Drug
Lead sponsor
Emory University
Other
Eligibility
19 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 2, 2026, 2:30 AM EDT
Completed Phase 3 Interventional Results available

Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer

NCT00038467
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Tamoxifen, Exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years and older · Female only
Enrollment
4,740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2013
U.S. locations
57
States / cities
Birmingham, Alabama • Green Valley, Arizona • Green Velley, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Oct 2, 2026, 2:30 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS)

NCT01257581
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
creatine, tamoxifen
Drug
Lead sponsor
Nazem Atassi
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
9
States / cities
Kansas City, Kansas • Boston, Massachusetts • Worcester, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Oct 2, 2026, 2:30 AM EDT
Completed Phase 2 Interventional Results available

Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

NCT00482391
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, cyclophosphamide, doxorubicin hydrochloride, lapatinib ditosylate, paclitaxel, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2017 · Synced Oct 2, 2026, 2:30 AM EDT
Completed Phase 2 Interventional Results available

Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

NCT02993159
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive
Interventions
Afimoxifene, Laboratory Biomarker Analysis, Placebo, Tamoxifen Citrate
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Chicago, Illinois • Edgewood, Kentucky • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 2, 2026, 2:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Endocrine Therapy Effects of Host Immunity in Early Stage Breast Cancer

NCT03719495
View directory record Official record
Conditions
Breast Cancer, Estrogen Receptor-positive Breast Cancer, Healthy
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 2, 2026, 2:30 AM EDT
Not listed Not applicable Interventional

Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast

NCT00126464
View directory record Official record
Conditions
Breast Cancer
Interventions
fulvestrant, tamoxifen citrate, conventional surgery, neoadjuvant therapy
Drug · Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Oct 2, 2026, 2:30 AM EDT
Completed Phase 3 Interventional

Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis

NCT00670319
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Raloxifene HCL, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
Up to 80 Years · Female only
Enrollment
7,705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1999
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 1, 2008 · Synced Oct 2, 2026, 2:30 AM EDT
Completed Phase 2 Interventional Results available

Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer

NCT02366130
View directory record Official record
Conditions
Breast Cancer
Interventions
Ra-223 dichloride, Denosumab, Hormone Therapy
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Oct 2, 2026, 2:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male Volunteers

NCT01821066
View directory record Official record
Conditions
Healthy
Interventions
PD-0332991 alone, Tamoxifen 60 mg, Tamoxifen 20 mg, PD-0332991 combination
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 2, 2026, 2:30 AM EDT
Completed Phase 1 Interventional

A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma

NCT00001436
View directory record Official record
Conditions
Neoplasm Metastasis, Osteosarcoma
Interventions
OncoLAR® (Registered Trademark), tamoxifen
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 2, 2026, 2:30 AM EDT
Completed Phase 1 Interventional

SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer

NCT00005822
View directory record Official record
Conditions
Breast Cancer
Interventions
doxorubicin hydrochloride, semaxanib, conventional surgery, radiation therapy, tamoxifen
Drug · Procedure · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2010 · Synced Oct 2, 2026, 2:30 AM EDT
Terminated No phase listed Observational

Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer

NCT00899197
View directory record Official record
Conditions
Breast Cancer
Interventions
tamoxifen citrate, gene expression analysis, protein expression analysis, immunoenzyme technique, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 2, 2026, 2:30 AM EDT
Completed Phase 1 Interventional

Trastuzumab and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer

NCT00009997
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, conventional surgery
Biological · Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Oct 2, 2026, 2:30 AM EDT
Completed Phase 2 Interventional Results available

Raloxifene for Women With Alzheimer's Disease

NCT00368459
View directory record Official record
Conditions
Alzheimer Disease
Interventions
raloxifene, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
60 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
4
States / cities
Santa Rosa, California • Stanford, California • Springfield, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Oct 2, 2026, 2:30 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Tamoxifen Versus Estradiol for Unscheduled Bleeding in Etonogestrel Implant Users, a Randomized Pilot Trial

NCT04933240
View directory record Official record
Conditions
Vaginal Bleeding
Interventions
Tamoxifen Citrate 10Mg Tab, Estradiol, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
15 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 3, 2022 · Synced Oct 2, 2026, 2:30 AM EDT
Completed Phase 2 Interventional Results available

The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer

NCT04129216
View directory record Official record
Conditions
Breast Cancer
Interventions
Tamoxifen Citrate, Letrozole, Exemestane, Blueprint, Mammaprint
Drug · Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 2, 2026, 2:30 AM EDT
Terminated Phase 2 Interventional

A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy

NCT01685255
View directory record Official record
Conditions
Ovarian Cancer, Genitourinary (GU) Tumors
Interventions
Epacadostat, tamoxifen
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2019 · Synced Oct 2, 2026, 2:30 AM EDT
Completed Not applicable Interventional

Diindolylmethane in Treating Patients With Breast Cancer

NCT01391689
View directory record Official record
Conditions
Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions
diindolylmethane, placebo
Dietary Supplement
Lead sponsor
University of Arizona
Other
Eligibility
19 Years and older · Female only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 2, 2026, 2:30 AM EDT
Completed Phase 2 Interventional Results available

Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors

NCT03382834
View directory record Official record
Conditions
HIV Infections
Interventions
Tamoxifen, Vorinostat, Antiretroviral drugs
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 2, 2026, 2:30 AM EDT
Completed Phase 2 Interventional Results available

Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.

NCT00240071
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Avastin, Hormonal therapy
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 80 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Oct 2, 2026, 2:30 AM EDT